Daniel B. Costa, MD, PhD, MMSc

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Dr. Costa is an Associate Professor of Medicine at Harvard Medical School and a Thoracic Medical Oncologist at Beth Israel Deaconess Medical Center (BIDMC). He is the co-director of the lung cancer research program within the Cancer Research Institute at BIDMC and the co-leader of the lung cancer program at Dana-Farber/Harvard Cancer Center. 

Dr. Costa earned his medical and doctoral degrees from the Universidade de São Paulo and Universidade Estadual de Campinas, respectively, both in Brazil. He completed his residency at the Yale University School of Medicine-affiliated program in Internal Medicine and his fellowship in Hematology/Oncology at BIDMC and received a master of medical sciences degree in clinical investigation from Harvard Medical School.

Dr. Costa is a clinical trial investigator and translational cancer researcher whose investigative work focuses on characterizing the mechanisms of sensitivity and resistance to tyrosine kinase inhibitors in lung cancers with oncogenic mutations or rearrangements.